https://www.yiliao.com/index.php?action=history&feed=atom&title=%E9%97%A8%E9%9D%99%E8%84%89%E7%99%8C%E6%A0%93
门静脉癌栓 - 版本历史
2026-04-18T21:51:41Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E9%97%A8%E9%9D%99%E8%84%89%E7%99%8C%E6%A0%93&diff=316536&oldid=prev
120.244.141.225：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-02-07T03:43:39Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>PVTT</strong>（Portal Vein Tumor Thrombus，门静脉癌栓）是<strong>[[肝细胞癌]]</strong>（HCC）晚期最常见的并发症之一，指癌细胞侵入并定植于门静脉系统形成的栓子。<br />
<br>在临床上，PVTT 的出现标志着肿瘤具有极高的侵袭性和不良预后。它不仅直接阻断肝脏血供，诱发难以控制的<strong>[[腹水]]</strong>和食管胃底静脉曲张破裂出血，还是癌细胞肝内播散和远处转移的“高速公路”。血清标志物 <strong>[[DCP]]</strong>（异常凝血酶原）的升高与 PVTT 的形成呈高度正相关。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">PVTT</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Portal Vein Tumor Thrombus (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">肝癌预后的分水岭</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">病理特征</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">原发疾病</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[肝细胞癌]] (HCC)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">发生率</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">44% - 62% (中晚期)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">相关标志物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">[[DCP]] > [[AFP]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">诊断金标准</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">增强 CT / MRI</td><br />
</tr><br />
<br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">临床分期</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">BCLC 分期</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #e11d48;">C 期 (晚期)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">常用分型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[程氏分型]] (中国)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">自然生存期</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #e11d48;">2.7 - 4.0 个月</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">鉴别诊断</th><br />
<td style="padding: 6px 12px; color: #1e40af;">良性血栓 (肝硬化)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">程氏分型：治疗的指南针</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
PVTT 的位置和范围直接决定了治疗策略的选择。目前中国临床主要采用<strong>程氏分型 (Cheng's Classification)</strong>：<br />
</p><br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 15%;">分型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 45%;">累及范围</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 40%;">推荐治疗策略</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">I 型</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">侵犯门静脉<strong>叶段分支</strong> (Microvascular)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">手术切除</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">II 型</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">侵犯门静脉<strong>左/右支</strong> (一级分支)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">手术切除 / [[TACE]]</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #e11d48;">III 型</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">侵犯门静脉<strong>主干</strong> (Main Trunk)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">TACE-碘125粒子 / 靶向+免疫</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #e11d48;">IV 型</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">侵犯<strong>肠系膜上静脉</strong> (SMV)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">系统治疗 / 支持治疗</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗困境：东西方差异</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
PVTT 的治疗在国际上存在显著争议。<br />
</p><br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>西方观点 (BCLC)：</strong> 只要出现 PVTT，即归为 <strong>BCLC C期</strong>（晚期），认为手术获益极低，主要推荐<strong>[[索拉非尼]]</strong>或阿替利珠单抗+贝伐珠单抗进行系统治疗。</li><br />
<li style="margin-bottom: 12px;"><strong>东方观点 (中国/日本)：</strong> 采取更积极的策略。对于 I/II 型甚至部分 III 型 PVTT，尝试<strong>手术切除</strong>及取栓，并结合 [[TACE]]（肝动脉化疗栓塞）、放疗及系统治疗，可显著延长生存期。</li><br />
<li style="margin-bottom: 0;"><strong>多模式联合：</strong> “TACE + 靶向药物 + 免疫检查点抑制剂”的三联疗法正成为控制 PVTT 的新趋势。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">关键相关概念 [Key Concepts]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
<strong>1. Cheng's Classification (程氏分型)：</strong> 由中国学者程树群教授提出。相比日本的 VP 分型，程氏分型更侧重于指导是否进行手术切除，是目前中国肝癌指南推荐的标准。<br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
<strong>2. Cavernous Transformation (海绵样变)：</strong> 当门静脉主干被癌栓或血栓慢性阻塞后，机体会代偿性地在其周围形成侧支循环，影像学上表现为蜂窝状或海绵状血管网。<br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
<strong>3. Tumor Thrombus vs. Bland Thrombus (癌栓与血栓)：</strong> 鉴别关键。癌栓在增强 CT 动脉期会有强化（因为有肿瘤新生血管供血），且常伴有门静脉管壁破坏；而普通血栓通常无强化。<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 20px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #ffffff;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Cheng SQ, et al. (2016).</strong> <em>A Novel Prognostic Staging System for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.</em> <strong>[[Ann Surg Oncol]]</strong>. <br><br />
<span style="color: #475569;">[点评]：系统阐述了程氏分型，证实了对于特定类型的 PVTT，手术切除优于非手术治疗。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Llovet JM, et al. (2008).</strong> <em>Sorafenib in advanced hepatocellular carcinoma.</em> <strong>[[N Engl J Med]]</strong>. <br><br />
<span style="color: #475569;">[点评]：SHARP 研究。确立了索拉非尼在合并 PVTT 的晚期肝癌中的一线治疗地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>CNLC Guidelines. (2024).</strong> <em>Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China.</em> <strong>[[NHC China]]</strong>. <br><br />
<span style="color: #475569;">[点评]：国家卫健委指南，明确推荐根据癌栓分型采取手术、TACE 或放疗等多学科综合治疗模式。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
肿瘤标志物 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">上级分类</td><br />
<td style="padding: 10px 15px; color: #334155;">[[肝细胞癌]] (并发症) • 血管侵犯</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">密切相关</td><br />
<td style="padding: 10px 15px; color: #334155;">[[DCP]] (强相关) • [[AFP-L3]] • [[腹水]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">治疗手段</td><br />
<td style="padding: 10px 15px; color: #334155;">[[TACE]] • 肝切除 • [[索拉非尼]] • 放疗</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
120.244.141.225